If you’re a member of the media working on a story about brain health, we can connect you with the experts at Cohen Veterans Bioscience. Please don’t hesitate to contact us.
Cohen Veterans Bioscience
Cohen Veterans Bioscience is a national nonprofit 501(c)(3) public charity research organization dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of veterans and civilians who suffer the devastating effects of trauma-related and other brain disorders.
Follow Cohen Veterans Bioscience
- Read more
Cohen Veterans Bioscience announces findings from a study which identifies a critical brain imaging biomarker that may help guide people who suffer from PTSD towards the most effective treatment.
CDISC and Cohen Veterans Bioscience Announce Release of First Data Standard to Improve Research for Post Traumatic Stress DisorderRead more
CDISC and Cohen Veterans Bioscience are pleased to announce the publication of a new Therapeutic Area (TA) Standard for Post Traumatic Stress Disorder released in the form of a User Guide for data managers, statisticians, programmers and study managers.
The Michael J. Fox Foundation Partners with Cohen Veterans Bioscience on BRAIN Commons, Harnessing the Power of Big Data for Brain DiseasesRead more
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Cohen Veterans Bioscience announce their partnership on BRAIN Commons, a platform designed to fuel the use of big data in brain disease research. It provides unprecedented access to research data and analytics.
Cohen Veterans Bioscience Receives Research Award from Department of Defense’s Medical Research and Materiel Command to Establish A Clinical Trial Infrastructure and Conduct an Adaptive Platform Trial Testing Post-Traumatic Stress Disorder (PTSD) PharmacotherapeuticsRead more
Cohen Veterans Bioscience will establish a clinical trial infrastructure and serve as the Clinical Coordinating Center for a 3.5-year study to comparatively test pharmacotherapeutics for PTSD.
- Read more
Early Signal subsidiary will expand CVB’s role as a hub for translational research and data analytics to fast-track solutions for brain disorders